94 related articles for article (PubMed ID: 11248422)
21. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
Ai Z; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
[TBL] [Abstract][Full Text] [Related]
22. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype.
Pan B; Yao KS; Monia BP; Dean NM; McKay RA; Hamilton TC; O'Dwyer PJ
Biochem Pharmacol; 2002 May; 63(9):1699-707. PubMed ID: 12007573
[TBL] [Abstract][Full Text] [Related]
23. Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy.
Vandier D; Calvez V; Massade L; Gouyette A; Mickley L; Fojo T; Rixe O
J Natl Cancer Inst; 2000 Apr; 92(8):642-7. PubMed ID: 10772682
[TBL] [Abstract][Full Text] [Related]
24. [Relationship between overexpression of the RIalpha subunit of the cAMP-dependent protein kinase and clinicopathological features of lung cancer].
Shi SS; He ZG; Shao K; Zhou F; Xiong MH; Huang W; Mu BD; Zhang CY; Zhang S; Sun YT; He J
Zhonghua Zhong Liu Za Zhi; 2004 Sep; 26(9):547-50. PubMed ID: 15555286
[TBL] [Abstract][Full Text] [Related]
25. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal--regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines.
Cui W; Yazlovitskaya EM; Mayo MS; Pelling JC; Persons DL
Mol Carcinog; 2000 Dec; 29(4):219-28. PubMed ID: 11170260
[TBL] [Abstract][Full Text] [Related]
27. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
[TBL] [Abstract][Full Text] [Related]
28. The role of expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin.
Chekhun VF; Lukyanova NY; Urchenko OV; Kulik GI
Exp Oncol; 2005 Sep; 27(3):191-5. PubMed ID: 16244579
[TBL] [Abstract][Full Text] [Related]
29. Lack of modulation of MDR1 gene expression by dominant inhibition of cAMP-dependent protein kinase in doxorubicin-resistant MCF-7 breast cancer cells.
Parissenti AM; Gannon BR; Villeneuve DJ; Kirwan-rhude AF; Chadderton A; Glück S
Int J Cancer; 1999 Sep; 82(6):893-900. PubMed ID: 10446459
[TBL] [Abstract][Full Text] [Related]
30. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
[TBL] [Abstract][Full Text] [Related]
31. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
32. Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells.
Wan J; Shi F; Xu Z; Zhao M
Int J Oncol; 2015 Dec; 47(6):2217-25. PubMed ID: 26498997
[TBL] [Abstract][Full Text] [Related]
33. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
34. Chemoprevention with protein kinase A RIalpha antisense in DMBA-mammary carcinogenesis.
Nesterova MV; Cho-Chung YS
Ann N Y Acad Sci; 2005 Nov; 1058():255-64. PubMed ID: 16394142
[TBL] [Abstract][Full Text] [Related]
35. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
[TBL] [Abstract][Full Text] [Related]
36. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
[TBL] [Abstract][Full Text] [Related]
37. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
Song K; Li Z; Seth P; Cowan KH; Sinha BK
Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
[TBL] [Abstract][Full Text] [Related]
38. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.
Bhatt M; Ivan C; Xie X; Siddik ZH
Oncotarget; 2017 Feb; 8(7):10905-10918. PubMed ID: 28038466
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin sensitivity in cAMP-dependent protein kinase mutants of Saccharomyces cerevisiae.
Cvijic ME; Yang WL; Chin KV
Anticancer Res; 1998; 18(5A):3187-92. PubMed ID: 9858882
[TBL] [Abstract][Full Text] [Related]
40. [Relationship between cytochrome c-mediated caspase-3 activity and chemoresistance in cisplatin-resistant human ovarian cancer cell lines].
Yang X; Zheng F; Xing H; Gao Q; Wang W; Lu Y; Wang S; Ma D
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):544-7. PubMed ID: 12667321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]